Corneal injury induced by ADC targeted drugs
Conditions
Interventions
ADC Treatment Group:Receiving ADC Therapy
Sponsors
Tianjin Medical University Eye Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Diagnosed with HER2-positive malignant tumor (breast cancer/gastric cancer, etc.), currently undergoing monotherapy or combination therapy with ADC-based targeted agents for >=1 month. 2. Best-corrected visual acuity (Snellen chart) >=0.1 at baseline examination. 3. The patients' medical records were comprehensive.
Exclusion criteria
Exclusion criteria: 1. Patients with hypersensitivity to the investigational drug. 2. Ocular conditions that may affect the study outcomes, such as blepharitis, conjunctivitis, keratitis, hordeolum (stye), or facial nerve palsy. 3. Subjects with a documented history of herpes simplex keratitis. 4. Concurrent clinically significant systemic disease. 5. Extensive dermatologic disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Corneal Fluorescein Staining Score (NEI Scale);Corneal Nerve Fiber Density (CNFD);Ocular Surface Disease Index (OSDI) Score;Best-Corrected Visual Acuity (BCVA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-Contact Intraocular Pressure (IOP); | — |
Countries
China
Contacts
Public ContactYang Ruibo
Tianjin Medical University Eye Hospital
Outcome results
None listed